Antiviral resistance and hepatitis B therapy
Marc G. Ghany, Edward C. Doo – 27 April 2009 – The management of chronic hepatitis B currently rests with long‐term therapy using oral nucleoside analogs. The major limitation of long‐term therapy is antiviral resistance. Antiviral resistance is due to the high rate of mutations that can occur during hepatitis B virus (HBV) replication and the selection of these mutants due to a replication advantage in the presence of the antiviral agent. Indeed, high rates of antiviral resistance have been found with long‐term use of lamivudine, in up to 76% of patients treated for 5 years or more.